La catena delle opzioni mostra i dati chiave delle opzioni azionarie di DBV Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per DBV Technologies..

DBV Technologies (NASDAQ:DBVT) Azioni, Quote.MetaTitle.option-chain

DBV Technologies

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

Absci

ADC Therapeutics

Akebia Therapeutics

Altimmune

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Emergent BioSolutions

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Immuneering Corporation - Class A Common Stock

Immuneering

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

Monopar Therapeutics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Verastem

DBV Technologies (DBVT) Previsione

Notizie

Utili

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Comments

DBV Technologies Catena di Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO